Standout Papers

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Ri... 2020 2026 2022 2024242
  1. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia (2020)
    Paolo Ghia, Andrzej Pluta et al. Journal of Clinical Oncology

Immediate Impact

2 from Science/Nature 57 standout
Sub-graph 1 of 21

Citing Papers

PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
2024 Standout
2 intermediate papers

Works of Małgorzata Wach being referenced

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
2020 Standout
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
2017

Author Peers

Author Last Decade Papers Cites
Małgorzata Wach 545 429 212 34 667
Sandra Kanan 518 460 167 23 743
A. M. Liberati 464 352 193 19 670
Luciano Levato 429 252 261 39 642
Petra Langerbeins 513 441 157 36 646
Andrew Lipsky 549 390 200 23 671
Sasanka M. Handunnetti 535 482 165 23 712
Marie‐Sarah Dilhuydy 365 322 133 29 590
James D’Rozario 544 386 252 25 846
Natali Pflug 429 363 106 26 656
Elizabeth Bilotti 573 451 378 29 814

All Works

Loading papers...

Rankless by CCL
2026